Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 3/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | HTR2B | P41595 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.56 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.56 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
| ▸ | NAE1 | Q13564 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6953505 | 0.93 | AGTR1 (0.51) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL684004 | 0.92 | AGTR2 (0.58) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL683999 | 0.92 | AGTR2 (0.60) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL683294 | 0.91 | AGTR2 (0.61) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL683298 | 0.91 | AGTR2 (0.62) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL684008 | 0.90 | AGTR2 (0.56) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL683341 | 0.90 | AGTR2 (0.56) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 | |
| SCHEMBL9197447 | 0.90 | — | — | |
| SCHEMBL9192379 | 0.89 | PPARG (0.46) | PPARG | |
| SCHEMBL906601 | 0.89 | AGTR2 (0.41) | AGTR2CYP3A4ADORA3ADRA2BSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277520-A2 | A pharmaceutical composition for angiotensin ii-mediated diseases | Takeda Pharmaceutical Company Limited (JP) | 2011-01-26 | — | — | EP | claimed |
| EP-1844774-A2 | A pharmaceutical composition for angiotensin II-mediated diseases | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | claimed |
| US-20040082636-A1 | Method for the prophylaxis or treatment of glomerulonephritis | TAKEDA CHEMICAL INDUSTRIES, LTD. | 2004-04-29 | — | — | US | claimed |
| US-6686383-B2 | TREATMENT OF DIABETIC NEPHROPATHY WITH A BIPHENYL-4-YL)ALKYL-1H-BENZIMIDAZOLE COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD (JP) | 2004-02-03 | — | — | US | claimed |
| EP-1306089-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists | Takeda Chemical Industries, Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| EP-1306088-A1 | Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic | Takeda Chemical Industries, Ltd. (JP) | 2003-05-02 | — | — | EP | claimed |
| EP-0720982-B1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-11-13 | — | — | EP | claimed |
| US-6469037-B2 | Prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-10-22 | — | — | US | claimed |
| EP-0612523-B1 | Vascular hypertrophy suppressor | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-06-12 | — | — | EP | claimed |
| US-20020045652-A1 | Prophylactic or therapeutic drug for renal diseases | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-04-18 | — | — | US | claimed |
| EP-0612524-B1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-08-26 | — | — | EP | claimed |
| US-5736561-A | ANGIOTENSIN II ANTAGONIST FOR PROPHYLAXIS OR TREATMENT AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, FOR VASCULAR RESTENOSIS AFTER BYPASS SURGERY AND FOR PROGRESSIVE ARTERIOSCLEROSIS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-04-07 | — | — | US | claimed |
| US-5605919-A | PREVENTION OF CELL INJURY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-02-25 | — | — | US | claimed |
| EP-0720982-A1 | Benzimidazole derivatives, their production and use and use as angiotensin II antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-07-10 | — | — | EP | claimed |
| WO-1995001176-A1 | USE OF AN ANGIOTENSIN II ANTAGONIST AS AN OCULAR HYPOTENSIVE AGENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1995-01-12 | — | — | WO | claimed |
| EP-0631780-A1 | Use of an angiotensin II antagonist as an ocular hypotensive agent | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| EP-0622077-A1 | Angiotensin II antagonists as a prophylactic or therapeutic drug for renal diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-02 | — | — | EP | claimed |
| EP-0612523-A1 | Vascular hypertrophy suppressor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0612524-A1 | Angiotensin II antagonists for the treatment of viral diseases | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-08-31 | — | — | EP | claimed |
| US-5328919-A | Antagonist of Angiotensin for cardiovascular disorders and hypotensive | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045652-A1 | Prophylactic or therapeutic drug for renal diseases | REN, SLC5A1, NR5A1 | AGTR2 542/4885CYP3A4 3149/4885ADORA3 3152/4885 |
| US-20040082636-A1 | Method for the prophylaxis or treatment of glomerulonephritis | REN, MSR1, MGST1 | AGTR2 231/4885CYP3A4 3212/4885ADORA3 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.